Turoctocog Alfa

Summary

Turoctocog Alfa (CHEMBL2108286) is an approved protein; indicated across 1 condition including hemophilia a.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• Indications: 1 condition
• Clinical trials: 18

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108286
Name	Turoctocog Alfa
Type	Protein
Max phase	4

Also known as: NN-7008, NN7008, Novoeight, Turoctocog alfa, TUROCTOCOG ALFA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hemophilia A	4	MONDO:0010602	MONDO:0010602

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
PHASE3	6
PHASE1	5
Not specified	5
PHASE4	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03449342	PHASE4	COMPLETED	Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period
NCT00840086	PHASE3	COMPLETED	Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects
NCT00984126	PHASE3	COMPLETED	Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015
NCT01138501	PHASE3	COMPLETED	Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
NCT01493778	PHASE3	COMPLETED	Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
NCT02938585	PHASE3	COMPLETED	Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A
NCT03588741	PHASE3	TERMINATED	Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial
NCT03196297	PHASE2	COMPLETED	A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
NCT00837356	PHASE1	COMPLETED	Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects
NCT01238367	PHASE1	COMPLETED	A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543
NCT01365520	PHASE1	COMPLETED	A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A
NCT01692925	PHASE1	COMPLETED	Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A
NCT02941354	PHASE1	COMPLETED	Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A
NCT06574984	Not specified	RECRUITING	Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients
NCT02035384	Not specified	COMPLETED	Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A
NCT02207218	Not specified	COMPLETED	To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan
NCT03179748	Not specified	COMPLETED	Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients
NCT04584892	Not specified	COMPLETED	Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational Activities

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).